Rani Therapeutics Holdings, Inc. Class A Share Price
RANIRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $1.12 | Prev. Close $1.23 | Circuit Range N/A |
Day Range $1.12 - $1.26 | Year Range $0.39 - $3.85 | Volume 37,695 |
Average Traded $1.21 |
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $1.12 | $1.22 | +10.41% |
05-Feb-26 | $1.18 | $1.10 | -8.30% |
04-Feb-26 | $1.24 | $1.21 | -2.82% |
03-Feb-26 | $1.21 | $1.24 | +2.48% |
02-Feb-26 | $1.20 | $1.21 | +0.83% |
30-Jan-26 | $1.28 | $1.20 | -6.98% |
29-Jan-26 | $1.33 | $1.29 | -4.09% |